XML 28 R14.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Major Customers and Concentration of Credit Risk | 12 Months Ended
--- | ---
Dec. 31, 2017
Risks and Uncertainties [Abstract] |
Major Customers and Concentration of Credit Risk | Major Customers and Concentration of Credit Risk
Customer | 2017 Revenue |  | % of Total Revenue |  | 2016 Revenue |  | % of Total Revenue |  | 2015 Revenue |  | % of Total Revenue
MedImmune | $ | 22,269,773 |  |  | 53 | % |  | $ | 1,518,639 |  |  | 4 | % |  | $ | 16,037,731 |  |  | 40 | %
DARPA | 9,983,927 |  |  | 24 |  |  | 26,602,183 |  |  | 75 |  |  | 11,582,623 |  |  | 28 |
Roche | 6,107,254 |  |  | 14 |  |  | 4,917,929 |  |  | 14 |  |  | 10,778,688 |  |  | 27 |
NIAID | — |  |  | — |  |  | 118,171 |  |  | — |  |  | 901,475 |  |  | 2 |
GeneOne (affiliated entity) | 551,208 |  |  | 1 |  |  | 1,188,432 |  |  | 4 |  |  | 450,000 |  |  | 1 |
All other | 3,307,924 |  |  | 8 |  |  | 1,023,007 |  |  | 3 |  |  | 821,594 |  |  | 2 |
Total revenue | $ | 42,220,086 |  |  | 100 | % |  | $ | 35,368,361 |  |  | 100 | % |  | $ | 40,572,111 |  |  | 100 | %
During the years ended December 31, 2017, 2016 and 2015, the Company recognized revenue from various license fees, collaborative research and development agreements, grants and government contracts. As of December 31, 2017, $4.1 million, or 69%, and $1.7 million, or 28%, of the Company's accounts receivable was attributable to DARPA and MedImmune, respectively. As of December 31, 2016, $12.1 million, or 73%, $2.4 million, or 15%, and $1.2 million, or 7%, of accounts receivable was attributable to DARPA, Roche and MedImmune, respectively. The Company’s accounts receivable from DARPA includes $1.6 million of amounts that are unbilled as of December 31, 2017. Unbilled amounts range from 1 to 9 months in age and are attributable to the fact that the Company is awaiting an invoice from its sub-contractor prior to submission of an aggregate invoice to DARPA. The Company believes that all criteria for revenue recognition under SAB 104 have been met, and also anticipates that all such amounts will be invoiced and collected within the next 12 months and has included these amounts as current assets in its consolidated balance sheet. There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.

X
- Definition The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -URI http://asc.fasb.org/topic&trid=2134479 + Details
Name: | us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration